Graduate Students

iPSC Seminars: Early Drug Discovery Unit (EDDU)

admin — Thu, 31 Jul 2025 15:32:34 +0000

THE NEURO'S EDDU iPSC SEMINAR SERIES

Modeling α-Synuclein Pathology Spreading in a 3D Human Midbrain-Striatal Assembloid

91�� researchers receive funding from the Canadian Cancer Society for cancer equity research

admin — Mon, 17 Feb 2025 20:31:39 +0000

Co-Principal Investigators Manisha Pahwa, CIHR Research Excellence, Diversity, and Independence Postdoctoral Fellow in the School of Physical and Occupational Therapy, and Professor Ananya Banerjee, from 91��'s Department of Epidemiology, Biostatistics, and Occupational Health, have been awarded $449,604 from the Canadian Cancer Society’s Health Equity Research Grant

Documentum services (D2, Webtop, and Records) will be unavailable August 5 from 12 p.m.- 1 p.m.

admin — Mon, 28 Jul 2025 12:32:10 +0000

Documentum services, including D2, Webtop, and Records, will be unavailable on Tuesday, August 5, 2025, from 12 p.m. to 1 p.m. due to scheduled system maintenance.

This work is necessary to ensure the continued performance and reliability of IT resources across the organization.

Who is affected

Anyone who uses a D2 space or accesses documents through the Documentum platform will be unable to upload or retrieve files.

What to do

If you have work that requires access to Documentum, please plan accordingly.

Prescribing anti-swelling drug reduces immune response weeks after last dose

admin — Wed, 26 Feb 2025 16:05:58 +0000

Mapping immune cell diversity reveals dexamethasone’s impact on brain cancer immunotherapy

Swelling caused by brain cancer is a problem that can lead to serious side effects and even death. While controlling swelling is important, a new study shows that a commonly prescribed anti-swelling drug suppresses the immune system for weeks after dosage, inhibiting the body’s ability to fight the cancer.

Latest Alzheimer’s drug shown less effective in females than males

admin — Tue, 18 Mar 2025 18:27:46 +0000

Since becoming only the second Alzheimer’s-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.

Alan Evans receives Order of Canada

admin — Mon, 30 Jun 2025 21:35:08 +0000

Career of breakthroughs in neuroimaging recognized with one of the nation’s highest honours

A career that took an uncharted trajectory has been recognized with the Order of Canada, one of the country’s top honours.

Expanding access to specialized healthcare across Quebec: ECHO Superhub at The Neuro

admin — Tue, 25 Mar 2025 18:37:02 +0000

Free, online training program strengthens training and brings specialized care to communities across Quebec

A healthcare telementoring program housed at The Neuro and supported by the Transforming Autism Care Consortium (TACC) is expanding its reach after achieving designation as an ECHO Superhub. Under the direction of Julie Scorah, PhD, this milestone ensures that specialized knowledge reaches underserved communities.

Achievements of clinicians and scientists recognized with King Charles III Coronation Medals

admin — Fri, 14 Mar 2025 13:09:39 +0000

Five clinicians and scientists at The Neuro have been awarded King Charles III Coronation Medals in recognition of their contributions to our understanding of neurological disease. The Coronation Medal commemorates the Coronation of His Majesty King Charles III as King of Canada. The medal is administered by the Chancellery of Honours at Rideau Hall.

Six principal investigators from The Neuro receive CIHR grants

admin — Mon, 10 Feb 2025 18:44:57 +0000

Projects include important research on Parkinson’s, glioblastoma and dementia

Project to create AI model for ALS receives Génome Québec funding

admin — Mon, 17 Mar 2025 15:29:17 +0000

$400,000 will fuel public-private collaboration to discover new disease biomarkers

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

AI analysis of healthcare records reveals key factors in autism diagnosis

admin — Wed, 26 Mar 2025 15:23:21 +0000

Scientists argue the criteria we use for diagnosing autism may need revision

Without clear and effective biological tests for autism based on genes, brain or blood measurements, diagnosis today still largely depends on clinical assessment. The standard way of doing this is by observing how the individual fits the criteria for autism listed in gold standard manuals like the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).

Genetic sequencing project receives more than $8 million in funding

admin — Tue, 18 Mar 2025 14:55:14 +0000

NeuRo Genomics Initiative will help better understand rare and aging-related neurological disorders affecting Canadians

A project led by Ziv Gan-Or, MD, PhD, at The Neuro (Montreal Neurological Institute-Hospital) of 91�� and Martine Tétreault, PhD, at Université de Montréal has received more than $8 million to sequence the genomes of 8,700 people, to map the role of genetics in neurological disorders.

Call for Applications:Graduate Impact Award Program Fall 2025

admin — Thu, 24 Jul 2025 13:39:41 +0000

Application Deadline: September 14, 2025, 11:59PM ET - Apply Here!

Application Deadline:Graduate Impact Award Program Fall 2025

admin — Thu, 24 Jul 2025 13:41:36 +0000